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A b s t r a c t
Introduction: Intravenous infusion of adenosine via the femoral vein is commonly used to achieve maximum hyperemia for 
fractional flow reserve (FFR) assessment in the catheterization laboratory. In the era of transradial access for coronary interventions, 
obtaining additional venous access with sheath insertion in the groin is unpractical and may be associated with a higher risk of 
bleeding complications. In a vast majority of cases, patients scheduled for the catheterization laboratory are already equipped with 
peripheral vein access in antecubital fossa vein. However, only limited data exist to support non-central vein infusion of adenosine 
instead of the femoral vein for FFR assessment.
Aim: To compare infusion of adenosine via a central versus a peripheral vein for the assessment of peak FFR.
Material and methods: We enrolled 50 consecutive patients with 125 borderline coronary lesions that were assessed by FFR 
using adenosine femoral and antecubital vein infusion of 140 µg/kg/min.
Results: Physiological severity assessed with femoral vein adenosine infusion at 140 µg/kg/min was mean 0.82 ±0.09, and with 
antecubital vein adenosine infusion at 140 µg/kg/min was 0.82 ±0.09. The mean time from initiation of adenosine infusion to max-
imal stable hyperemia was significantly shorter for 140 µg/kg/min femoral vein infusion as compared to antecubital vein infusion 
(49 ±19 s vs. 68 ±23 s; p < 0.001). There was a strong correlation between FFR values obtained from 140 µg/kg/min femoral and 
antecubital vein infusion (r = 0.99; p < 0.001).
Conclusions: Antecubital vein adenosine infusion achieved FFR values are very similar to those obtained using femoral vein 
adenosine administration. However, time to maximal hyperemia is longer with infusion via the antecubital vein.
Key words: coronary artery disease, adenosine, fractional flow reserve, borderline lesion, physiology.
S u m m a r y
Intravenous infusion of adenosine via the femoral vein is commonly used to achieve maximum hyperemia for fractional 
flow reserve (FFR) assessment in the catheterization laboratory. In the era of transradial access for coronary interventions, 
obtaining additional venous access for sheath insertion in the groin is impractical and may be associated with a higher risk of 
bleeding complications. In a vast majority of cases, patients scheduled for the catheterization laboratory are already equipped 
with peripheral vein access in the antecubital fossa vein. However, only limited data exist to support non-central vein infusion 
of adenosine instead of femoral vein infusion for an all-comers population of patients and lesions. The purpose of this study 
was to compare infusion of adenosine via a central versus a peripheral vein for the assessment of peak FFR.
Introduction
Coronary pressure-derived fractional flow reserve 
(FFR) is the current standard of care for the functional 
assessment of lesion severity in patients with interme-
diate-grade stenosis (typically around 40–90% stenosis) 
without evidence of ischemia in non-invasive testing, or 
in those with multivessel disease [1–6]. The FFR value of 
≤ 0.80 defines hemodynamically relevant lesions requir-
ing revascularization, while the FFR threshold of ≤ 0.75 is 
used to define more severe ischemia that is of prognostic 
relevance. Achievement of maximal hyperemia is crucial 
for appropriate and accurate FFR assessment and can be 
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obtained either with intravenous infusion of adenosine 
via a central vein (usually femoral) or intracoronary bo-
luses of adenosine [7]. In the era of transradial access 
for percutaneous coronary interventions (PCI), obtain-
ing additional venous access for sheath insertion in the 
groin is impractical and may be associated with a higher 
risk of complications if the patient has already received 
heparin. In a vast majority of cases, patients scheduled 
for the catheterization laboratory are already equipped 
with peripheral vein access in the antecubital fossa vein, 
which can also be used for adenosine infusion. However, 
only limited data exist to support non-central vein infu-
sion of adenosine instead of femoral vein infusion for an 
all-comers population of patients and lesions [8, 9]. 
Aim
The purpose of this study was to compare infusion 
of adenosine via a  central vs. a peripheral vein for the 
assessment of peak FFR.
Material and methods
Consecutive patients with stable angina between 18 
and 90 years of age with angiographically borderline ste-
nosis (40–90% diameter stenosis by visual assessment) 
in a major epicardial coronary artery, who were scheduled 
for FFR, were prospectively enrolled. Baseline clinical data 
were collected. Patients with acute myocardial infarction 
in the prior 30 days or contraindication to adenosine were 
excluded. Ethics approval was granted from the institu-
tional ethics review process and all patients gave written 
informed consent. Coronary angiography was performed 
with the femoral or radial approach based individual oper-
ator preferences. All procedures were performed by expe-
rienced operators in a cardiac reference university center 
with > 100 FFR assessments per year each. Patients had 
intravenous access established before the pressure-wire 
procedure using a pink (20-gauge) cannula placed in the 
antecubital fossa vein. For the femoral venous adminis-
tration of adenosine, a 6 Fr venous sheath with a  side 
arm was used. The infusion system was filled with ade-
nosine to exclude the wash-out period of the saline. The 
s5/s5i console and Verrata Pressure Guide Wire (Philips 
Volcano Corporation, San Diego, California) were used in 
all cases. A Launcher coronary guide catheter (Medtron-
ic, Minneapolis, USA) without side holes was used in all 
cases. Data acquisition included electrocardiographic sig-
nal recording. After intracoronary nitrates (300 µg) and 
acquisition of coronary angiograms, aortic pressure (Pa) 
and intracoronary distal pressure (Pd) were recorded in 
the following pattern. First, the pressure wire was zeroed 
and equalized, and its correct equalization (Pd/Pa ratio 
of 1.00 ±0.01) was confirmed during a 10-second acqui-
sition in the ascending aorta in each case. Afterward, 
the pressure sensor was positioned distal to the index 
stenosis and the guiding catheter was flushed with sa-
line and disengaged from the coronary ostium. Baseline 
pressures were recorded for at least 20 s before inducing 
hyperemia. Adenosine administration through a femoral 
or antecubital fossa vein at a rate of 140 for a minimum 
of 3 min and a pressure wire pullback maneuver to check 
for pressure drift were mandatory. Firstly, we performed 
an infusion through the antecubital vein. After waiting 
for the wash-out period of adenosine and Pd/Pa returned 
to its baseline value, 300 µg of nitrates was given, fol-
lowed by a saline flush of the guiding catheter. Then, an 
adenosine infusion through the femoral vein at 140 µg/
kg/min for the same lesion assessment was performed. 
In the same pressure recording, the bookmarks for core 
laboratory analyses were placed: 1) when adenosine in-
fusion started; 2) when the pullback maneuver started; 
and 3) when the pressure sensor reached the tip of the 
guiding catheter. If a Pd/Pa ratio < 0.99 or > 1.01 at the 
catheter tip was documented, the protocol mandated 
repeat assessment. This stepwise protocol was used for 
the assessment of every single coronary artery.
The FFR was experimentally and clinically validated 
under conditions of maximum and stable hyperemia 
[10] and was automatically calculated by software (ver. 
2.4.1.2723, Volcano) as the minimum Pd/Pa ratio found 
in the pressure recording. However, during intravenous 
adenosine infusion, the minimum hyperemic Pd/Pa ratio 
might develop before stabilization of hyperemia. Hence, 
conforming to its original validation [11, 12], core lab-
oratory analyses included a  thorough review of pres-
sure recordings to corroborate that FFR was calculated: 
1) after initiation of adenosine infusion; 2) within sta-
ble hyperemia; and 3) before the pullback maneuver. 
Stable hyperemia was defined as the plateau in mean 
Pa after stabilization of changing hemodynamics follow-
ing the initiation of adenosine infusion and before the 
pullback maneuver [10]. If a plateau was not clearly ob-
served, stable hyperemia was then defined as the period 
of pressure recording in which no further systematic fall 
in Pa was observed, following the initiation of adenos-
ine infusion but before the initiation of the pullback [10]. 
Within stable hyperemia, the minimum Pd/Pa ratio was 
then labeled as FFR. Core laboratory analyses included an 
evaluation of pressure waveforms to confirm that none 
of the following exclusion criteria were present: inappro-
priate normalization of the pressure wire (Pd/Pa ratio 
< 0.99 or > 1.01), ECG artifacts or significant arrhythmias 
in the first 20 s of the recording, loss of Pa or Pd signals 
at any point during the recording, automatic calculation 
pitfalls (identification of FFR during ectopic beats, Pa or 
Pd noise, wire whipping artifacts, etc.), dampening of Pa 
or Pd waveforms, pressure drift higher than < 0.99 or 
> 1.01, and absence of ECG or pressure-pullback record-
ing. The core laboratory also assessed the time to reac-
tion, defined as the time period from the beginning of ad-
enosine infusion to the initial drop of Pd/Pa, and time to 
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peak hyperemia, defined as the time from the beginning 
of adenosine infusion to the lowest stable Pd/Pa value.
Quantitative coronary angiography was performed by 
an independent core laboratory analyzer blinded to the 
results of FFR. Using the guide catheter for calibration 
and an edge detection system (CAAS 5.7 QCA system, Pie 
Medical), the reference vessel diameter and minimum lu-
men diameter were measured, and the percent diameter 
stenosis was calculated.
Statistical analysis
Categorical variables were expressed as numbers of pa-
tients (percentages). Continuous variables were expressed 
as mean ± standard deviation (SD). Non-normally distrib-
uted data were reported as median (interquartile range 
(IQR)). Agreement among tested methods was assessed by 
Bland-Altman plots and 95% limits of agreement. All tests 
were 2-tailed, and a p-value < 0.05 was considered statis-
tically significant. All statistical analyses were performed 
using Statistica 12.0 (StatSoft Inc, Tulsa, OK).
Results
Study population
Fifty patients with 125 borderline coronary artery ste-
noses were enrolled. Baseline patients’ and lesion char-
acteristics are presented in Tables I and II. Overall, mean 
age was 66.0 ±9.3 years, and 72% of patients were male. 
All patients presented with stable angina, which was an 
indication for the coronary angiography. The left anterior 
descending artery was the most commonly interrogated 
vessel (36.8%). 
Procedural data
Procedural success was 100% for advancing the pres-
sure wire distally to the stenosis. In general, the study 
population was composed of coronary stenoses of inter-
mediate angiographic severity (diameter stenosis 44.2 
±11.7 by quantitative angiographic assessment). Figure 1 
shows the distribution of the FFR values in the study, 
obtained from femoral infusion. The mean FFR was 0.82 
±0.09. There were no major procedure-related compli-
cations. Adenosine caused an asymptomatic transient 
atrioventricular block of third degree in 5.8% of patients. 
Chest pain occurred in 13.6% of patients. Based on FFR 
assessment, 42% of patients were scheduled for conser-
vative treatment, 46% were treated with PCI and 12% 
were scheduled for coronary artery bypass surgery. In pa-
tients who underwent FFR-guided PCI, FFR after the pro-
cedure was 0.87 ±0.02 (median 0.87 with IQR 0.86-0.9).
FFR findings and analysis
The mean FFR for femoral vein adenosine infusion 
at 140 µg/kg/min was 0.82 ±0.09 (median: 0.83, IQR: 
0.77–0.88) and for antecubital fossa vein adenosine in-
Table I. Study population and procedural data (n = 50)
Parameter Value
Age [years] 66.0 ±9.3
Male sex 36 (72.0)
Height [cm] 169.9 ±7.9
Weight [kg] 80.4 ±13.3
Body mass index [kg/m2] 27.8 ±3.7
Arterial hypertension 50 (100.0)
Diabetes mellitus 28 (56.0)
Previous myocardial infarction 26 (52.0)
Previous PCI 24 (48.0)
Previous CABG 0 (0.0)
Peripheral arterial disease 2 (4.0)
Chronic obstructive pulmonary disease 1 (2.0)
Previous stroke/TIA 0 (0.0)
Hyperlipidemia 50 (100.0)
Smoking 20 (40.0)
Serum creatinine [μmol/l] 91.1 ±19.4
LVEF (%) 52.8 ±8.1
Heart rate [beat/min] 71.5 ±9.7

















Values presented as number (percentage), mean ± standard deviation or medi-
an (interquartile range). CABG – coronary artery bypass grafting, CCS – Cana-
dian Cardiovascular Society, LVEF – left ventricle ejection fraction, NYHA – New 
York Heart Association, PCI – percutaneous coronary intervention, TIA – tran-
sient ischemic attack.
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fusion at 140 µg/kg/min 0.82 ±0.09 (median: 0.83, IQR: 
0.76–0.89). 
The percentage of functionally significant lesions ac-
cording to different methods of adenosine administra-
tion are presented in Figure 2 A. Figure 2 B shows the 
scatterplot of the relationship of FFR values for 140 µg/
kg/min femoral, antecubital fossa vein adenosine infu-
sion. There was a strong correlation between FFR values 
obtained from 140 µg/kg/min femoral and antecubital 
fossa vein infusion (r = 0.99; p < 0.001, Figure 3). 
The mean time from the initiation of adenosine in-
fusion to the beginning of pressure gradient drop was 
monitored and was significantly shorter when measured 
during 140 µg/kg/min femoral vein infusion as compared 
to 140 µg/kg/min antecubital vein infusion (31 ±14 s; 
median: 28, IQR: 21–37 s vs. 46 ±18 s; median: 44, IQR: 
34–50 s; p < 0.001).
Also, the time from the initiation of adenosine infu-
sion to the maximal stable hyperemia was significant-
ly shorter for 140 µg/kg/min femoral vein infusion as 
compared to 140 µg/kg/min antecubital vein infusion 
(49 ±19 s; median: 46, IQR: 35–58 s vs. 68 ±23 s; medi-
an: 63, IQR: 53–76 s; p < 0.001) – Figure 4. Additionally, 
we performed a  paired differences analysis comparing 
140 µg/kg/min femoral with 140 µg/kg/min antecubi-
tal fossa vein infusion and found no difference between 
femoral and antecubital infusion FFR values with mean 
delta of 0.001 (95% CI: –0.003 to 0.0005; p = 0.16).
Discussion
Our study identified the optimal way and dose of ad-
enosine administration for the reliable measurement of 
coronary FFR for assessment of the hemodynamic sever-
ity of borderline coronary stenoses. Femoral and antecu-
bital fossa vein infusion showed almost the same but not 
identical FFR values after achieving maximal and stable 
hyperemia. However, no systematic direction of bias was 
evident from Bland-Altman analysis. Moreover, maximal 
hyperemia takes longer to obtain with the antecubital 
vein compared to a large peripheral vein. 








Quantitative coronary angiography results:
Lesion length [mm] 21.7 ±14.0
RVD [mm] 2.6 ±0.6
MLD [mm] 1.4 ±0.4
DS (%) 44.2 ±11.7
Eccentric lesion 67 (53.6)
Moderate/severe tortuosity 52 (41.6)
Irregular contours 11 (9.2)
Moderate/severe calcifications 49 (40.8)
Ostial lesion 11 (9.2)
Values presented as number (percentage) or mean ± standard deviation. 
Cx – circumflex artery, Dg – diagonal branch, DS – diameter stenosis, LAD – left 
anterior descending artery, LMCA – left main coronary artery, Mg – marginal 
branch, MLD – minimal lumen diameter, RCA – right coronary artery, RVD – ref-
erence vessel diameter.
Figure 1. Distribution of the %DS (A) and fractional flow reserve (B) values in the study population
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This finding, in our opinion, is crucial and timely, as in 
everyday clinical practice there still seem to be questions 
and doubts about the optimal way of intravenous ade-
nosine administration.
Coronary pressure-derived FFR is the current standard 
of care for the functional assessment of lesion severity 
in patients with intermediate-grade stenosis (typically 
around 40–90% stenosis) without evidence of ischemia 
in non-invasive testing, or in those with multivessel dis-
ease [13].
The value 0.80 is the accepted FFR cut-off for defin-
ing hemodynamically relevant lesions requiring revascu-
larization. However, the FFR threshold of 0.75 is also used 
to define more severe ischemia that is of prognostic rel-
evance [5, 6]. In contrast to previously published data, in 
our study, we assessed more “severe” moderate lesions 
with FFR values < 0.80 and < 0.75 [8, 9] and confirmed 
the utility of peripheral vein adenosine infusion.
Central (femoral) venous infusion of adenosine has 
been the gold standard method of obtaining hyperemia 
for FFR measurement [7, 14–17] and could induce hy-
peremia with more reliable hyperemic efficacy than in-
tracoronary bolus injection [18–20]. However, it requires 
an additional puncture of the femoral vein, which may 
increase the risk of vascular complications. Also, it is not 
so convenient to use during the transradial approach, 
which is the method of choice in the majority of cathe-
terization laboratories worldwide, especially in patients 
Figure 2. A – Scatterplot presenting fractional flow reserve (FFR) values for 140 µg/kg/min femoral and ante-
cubital fossa vein adenosine infusion. B – Percentage of functionally significant lesions according to different 
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Figure 3. A  – Correlation of fractional flow reserve (FFR) values between 140 µg/kg/min femoral and  
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Figure 4. A – Femoral and antecubital fossa vein adenosine administration for individual cases with the line 
of identity. B – Mean times to peak hyperemia with femoral and antecubital fossa vein adenosine infusion.  
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scheduled for elective coronary angiography. The use of 
a combination of the transradial access and FFR-based 
lesion assessment is rapidly becoming a standard of care 
in many clinical situations, and the issue of adenosine 
delivery and the dose is therefore relevant and timely. 
Therefore an increasing frequency of peripheral venous 
adenosine administration for FFR has been noted, de-
spite doubts whether a  small cannula would actually 
generate adequate and sufficiently stable coronary hy-
peremia compared with a central venous infusion. In our 
study, we selected the antecubital fossa vein as a route 
of adenosine infusion, as this site is the most common 
in patients undergoing coronary angiography. To provide 
adequate hyperemia, we used a 20-gauge needle in each 
case. In our study, antecubital vein infusion of adenosine 
was as effective as femoral vein infusion in the induction 
of maximal hyperemia. There was no difference in mean 
FFR between these two ways of adenosine administra-
tion, and the number of functionally significant stenoses 
was not different between femoral vein and antecubital 
vein infusions of adenosine. In addition to FFR, the mean 
hyperemic transit time was also compared, and we found 
that the time to maximal hyperemia was longer with an-
tecubital vein infusion of adenosine than with femoral 
vein infusion. In our study, the mean difference of time to 
maximal hyperemia was 14 s, comparable to data previ-
ously published [8, 9]. Our results together with previous-
ly available data suggest that the infusion time should be 
long enough (at least 2 min) when the antecubital vein is 
selected for adenosine infusion for FFR assessment. Our 
results are in agreement with previous studies; however, 
we have assessed more lesions [8, 9]. Our findings sup-
port a strategy of using peripheral venous adenosine ad-
ministration as the default approach. The occasional FFR 
difference between access routes may actually be due to 
the intrinsic variability of the test itself and independent 
of whether adenosine is administered via peripheral and 
central vein infusion [21]. 
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Study limitations
The FFR procedures were performed by two experi-
enced operators at a single center but interobserver vari-
ability was not assessed. However, individual operator 
technique was formalized using local and study guide-
lines, and data analysis was performed by a core labora-
tory blinded to the results. We did not compare infusion 
of adenosine from differing peripheral access sites (e.g., 
back of the hand, wrist, and forearm). Ostial lesions of 
the right coronary artery or left main as well as tandem 
lesions were not included. In this study, we also did not 
compare results with intracoronary adenosine adminis-
tration.
Conclusions
Antecubital fossa vein adenosine infusion achieved 
FFR values are very similar to those obtained using fem-
oral vein adenosine administration. However, time to 
maximal hyperemia is longer with infusion via the ante-
cubital vein. 
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